Compare Expensify Inc (EXFY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Recursion Pharmaceuticals Inc — how do they compare? Expensify Inc trades at $2.3 (market cap $208.82M), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 10.2× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EXFY | RXRX | |
|---|---|---|
Market Cap | $208.82M | $2.14B |
Volume | 456,102 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $2.72 | $6.79 |
52-Week Low | $0.75 | $2.84 |
Typical Hold Time | 41 Days | 22 Days |
Enterprise Value | $148.44M | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.27, up 1.79% with a neutral technical signal. The company shows mixed fundamentals with revenue stabilizing around $140M but persistent net losses. Recent quarters show earnings improvement with two beats, while analyst consensus is bullish with a $13.75 price target. Business developments include AI integrations and European expansion of corporate card offerings.
The outlook remains speculative given negative profitability metrics, though cash flow improvements and strategic partnerships provide potential catalysts. Key risks include competitive pressure in expense management and the challenge of achieving sustainable profitability. The significant gap between current price and analyst targets suggests upside potential if execution improves.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
